To ask the Secretary of State for Work and Pensions what assessment he has made of the effect on his Department’s expenditure on social security benefits of the National Institute for Health and Clinical Excellence’s decision to withdraw eligibility of those suffering from the early stages of Alzheimer’s disease to have the drugs (a) Donepezil, (b) Rivastigmine and (c) Galantamine prescribed on the NHS. (102771)

Changes in the prescribing arrangements for people in the early stages of Alzheimer’s disease are unlikely to have any effects on the Department’s expenditure.